Integra LifeSciences IART Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenues by Business | ||||||
| Specialty Surgery | $283.14M— | —— | —— | —— | $280.66M— | |
| Tissue Reconstruction | $108.78M— | —— | —— | —— | $101.99M— | |
| Operating Income (Loss) by Business | ||||||
| Specialty Surgery | $83.13M— | —— | —— | —— | $72.22M— | |
| Tissue Reconstruction | $20.27M— | —— | —— | —— | $4.44M— | |
| Cost of goods sold by Business | ||||||
| Specialty Surgery | $110.48M— | —— | —— | —— | $109.86M— | |
| Tissue Reconstruction | $37.46M— | —— | —— | —— | $49.27M— | |
| SG&A by Business | ||||||
| Specialty Surgery | $77.68M— | —— | —— | —— | $83.79M— | |
| Tissue Reconstruction | $43.53M— | —— | —— | —— | $42.3M— | |
| Costs and Expenses by Business | ||||||
| Specialty Surgery | $200.01M— | —— | —— | —— | $208.44M— | |
| Tissue Reconstruction | $88.52M— | —— | —— | —— | $97.55M— | |
| R&D by Business | ||||||
| Specialty Surgery | $11.85M— | —— | —— | —— | $14.8M— | |
| Tissue Reconstruction | $7.53M— | —— | —— | —— | $5.97M— | |
| Foreign currency translation by Business | ||||||
| Specialty Surgery | -$1.07M— | —— | —— | —— | —— | |
| Tissue Reconstruction | -$841K— | —— | —— | —— | —— | |
| Intangible asset amortization by Business | ||||||
| Specialty Surgery | $0— | —— | —— | —— | $0— | |
| Tissue Reconstruction | $0— | —— | —— | —— | $0— | |
| Goodwill by Business | ||||||
| Specialty Surgery | $343.1M-0.3% | $344.17M— | —— | —— | —— | |
| Tissue Reconstruction | $270.15M-0.3% | $270.99M— | —— | —— | —— | |
| Total Revenues by Product | ||||||
| ENT | $37.71M-15.9% | $44.82M+9.7% | $40.87M-2.4% | $41.89M+7.9% | $38.8M-10.9% | |
| Instruments | $47.23M-9.7% | $52.29M+4.3% | $50.15M-5.5% | $53.08M+4.2% | $50.95M-0.2% | |
| Neurosurgery | $198.2M-12.4% | $226.2M+12.2% | $201.56M-3.6% | $208.99M+9.5% | $190.91M-13.3% | |
| Private Label | $29.14M-7.9% | $31.64M+24.1% | $25.49M-5.2% | $26.9M-1.1% | $27.21M+2.9% | |
| Wound Reconstruction | $79.65M-0.4% | $79.97M-4.8% | $83.99M-0.9% | $84.75M+13.3% | $74.78M-26.4% | |
| Total Revenues by Geography | ||||||
| Asia Pacific | $45.21M-15.9% | $53.73M+25.9% | $42.68M-10.6% | $47.73M+5.8% | $45.11M+2.4% | |
| Europe | $39.96M-4.5% | $41.85M-2.4% | $42.89M+0.7% | $42.59M+20.6% | $35.33M-15.6% | |
| Rest of World | $17.36M-8.4% | $18.96M-8.1% | $20.64M+8.8% | $18.97M-5.2% | $20.01M-3.4% | |
| United States | $289.38M-9.7% | $320.37M+8.3% | $295.85M-3.4% | $306.31M+8.5% | $282.22M-16.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Integra LifeSciences break its business down?
- Integra LifeSciences (IART) reports total revenues by business across 2 parts — Specialty Surgery and Tissue Reconstruction. Each is extracted from the segment footnotes and tracked over time.
- Where does Integra LifeSciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Integra LifeSciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
